These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 28500860

  • 1. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR.
    Cochrane Database Syst Rev; 2017 May 13; 5(5):CD012389. PubMed ID: 28500860
    [Abstract] [Full Text] [Related]

  • 2. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ, Kimber C, Hopewell S, Trivella M, Doree C, Abboud MR.
    Cochrane Database Syst Rev; 2020 Apr 06; 4(4):CD012389. PubMed ID: 32250453
    [Abstract] [Full Text] [Related]

  • 3. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ, Kohli R, Hopewell S, Trivella M, Wang WC.
    Cochrane Database Syst Rev; 2020 Jul 27; 7(7):CD003146. PubMed ID: 32716555
    [Abstract] [Full Text] [Related]

  • 4. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC.
    Cochrane Database Syst Rev; 2017 Jan 17; 1(1):CD003146. PubMed ID: 28094851
    [Abstract] [Full Text] [Related]

  • 5. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM, Hopewell S, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 Aug 01; 8(8):CD012082. PubMed ID: 30067867
    [Abstract] [Full Text] [Related]

  • 6. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ.
    Cochrane Database Syst Rev; 2017 Jul 03; 7(7):CD012380. PubMed ID: 28672087
    [Abstract] [Full Text] [Related]

  • 7. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB, Carpenter A, Dale-Harris I, Dorée C, Estcourt LJ.
    Cochrane Database Syst Rev; 2023 Aug 04; 8(8):CD012380. PubMed ID: 37539955
    [Abstract] [Full Text] [Related]

  • 8. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ, Kimber C, Trivella M, Doree C, Hopewell S.
    Cochrane Database Syst Rev; 2020 Jul 02; 7(7):CD003149. PubMed ID: 32614473
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ, Jones AP, Howard J.
    Cochrane Database Syst Rev; 2017 Apr 20; 4(4):CD002202. PubMed ID: 28426137
    [Abstract] [Full Text] [Related]

  • 10. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE, Nevitt SJ.
    Cochrane Database Syst Rev; 2022 Sep 01; 9(9):CD002202. PubMed ID: 36047926
    [Abstract] [Full Text] [Related]

  • 11. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Wang WC, Dwan K.
    Cochrane Database Syst Rev; 2013 Nov 14; (11):CD003146. PubMed ID: 24226646
    [Abstract] [Full Text] [Related]

  • 12. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ, Fortin PM, Trivella M, Hopewell S.
    Cochrane Database Syst Rev; 2016 Apr 06; 4(4):CD003149. PubMed ID: 27049331
    [Abstract] [Full Text] [Related]

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 14. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG, Greenhalgh J, Osipenko L, Venkatachalam M, Boland A, Dundar Y, Marsh K, Dickson R, Rees DC.
    Health Technol Assess; 2012 Feb 01; 16(43):1-129. PubMed ID: 23140544
    [Abstract] [Full Text] [Related]

  • 15. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NLC, Cohen AR, Pressel S, Adams RJ.
    Lancet; 2016 Feb 13; 387(10019):661-670. PubMed ID: 26670617
    [Abstract] [Full Text] [Related]

  • 16. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 17. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.
    Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Hambleton IR, Cho G.
    Cochrane Database Syst Rev; 2016 May 20; (5):CD008360. PubMed ID: 27198469
    [Abstract] [Full Text] [Related]

  • 18. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.
    Estcourt LJ, Hopewell S, Trivella M, Hambleton IR, Cho G.
    Cochrane Database Syst Rev; 2019 Oct 25; 2019(10):. PubMed ID: 31684693
    [Abstract] [Full Text] [Related]

  • 19. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE, Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).
    Am J Hematol; 2013 Nov 25; 88(11):932-8. PubMed ID: 23861242
    [Abstract] [Full Text] [Related]

  • 20. Pathogen-reduced platelets for the prevention of bleeding.
    Estcourt LJ, Malouf R, Hopewell S, Trivella M, Doree C, Stanworth SJ, Murphy MF.
    Cochrane Database Syst Rev; 2017 Jul 30; 7(7):CD009072. PubMed ID: 28756627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.